Breaking New Ground: Milsaperidone Offers Patients a Fresh Option for Serious Mental Illness

Vanda Pharmaceuticals has achieved a significant regulatory milestone with the FDA's approval of milsaperidone (Bysanti), a newly designated atypical antipsychotic medication poised to help adults battling schizophrenia and acute bipolar…

Continue Reading Breaking New Ground: Milsaperidone Offers Patients a Fresh Option for Serious Mental Illness

FDA Escalates Scrutiny of GLP‑1 Compounders as Industry Reports Key Clinical and Regulatory Updates

As reported by BioPharmaDive, he Food and Drug Administration (FDA) has intensified its oversight of companies marketing compounded GLP‑1 therapies, while Intellia Therapeutics, United Therapeutics, Merck & Co., and federal…

Continue Reading FDA Escalates Scrutiny of GLP‑1 Compounders as Industry Reports Key Clinical and Regulatory Updates